Nephros, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Financial amounts below are in U.S. dollars; unless noted, amounts are in millions. Nephros develops and sells water filtration products to medical and commercial markets. Its former Pathogen Detection Systems business is reported as discontinued operations; its SRP subsidiary, which developed a hemodiafiltration system, is being wound down.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 / comparator |
|---|---|---|
| Revenue | $3.697 | $2.159; up 71% |
| Gross profit / margin | $2.111 / 57% | $1.053 / 49% |
| Operating loss from continuing operations | $0.306 | $1.547 |
| Net loss | $0.306 | $1.967, including $0.406 loss from discontinued operations |
| Net loss per share attributable to Nephros shareholders | $0.03 | $0.20 |
| Cash from operating activities | $0.276 provided | $1.797 used |
| Cash and cash equivalents | $3.836 at March 31 | $3.634 at December 31, 2022 |
| Working capital | $6.909 | $6.849 at December 31, 2022 |
| Total liabilities | $2.033 | $2.118 at December 31, 2022 |
The secured note was paid off during the quarter. Remaining material financing obligations include lease liabilities of $0.931 million. The company reported no investing cash flows in Q1 2023; financing activities used $0.074 million, primarily for debt payments.
Material changes and management commentary
- Revenue increased by $1.538 million. Management attributed approximately 40% growth to core, programmatic business, supported by increased medical sales staffing and a commercial master distributor. An unusually large emergency-response order contributed approximately $0.6 million of revenue.
- Gross margin rose eight percentage points, which management attributed to 2022 price increases, lower shipping costs, and improved inventory management. Management described 55%–60% as its target gross-margin range.
- Operating expenses declined to $2.417 million from $2.600 million, mainly reflecting lower R&D after SRP’s wind-down and expense management. Operating loss narrowed from $1.547 million to $0.306 million.
- Operating cash flow improved by $2.073 million year over year, reflecting lower losses and working-capital movements. Inventory reduction provided about $0.8 million of cash, partly offset by about $0.7 million used by increased receivables.
- SRP’s board and stockholders approved a wind-down in March 2023 after the company could not secure a commercial partner or additional funding for its FDA-cleared HDF2 system. Nephros expects to receive SRP’s remaining assets, including HDF2 intellectual property, in partial repayment of an intercompany loan of approximately $1.5 million; repayment in cash is not expected. SRP filed a certificate of dissolution in April.
Outlook, risks, and contingencies
- Nephros reported an accumulated deficit of $143.1 million and stated that continuing operating losses and a history of negative operating cash flows raise substantial doubt about its ability to continue as a going concern. Management believes expense reductions, the PDS sale, SRP wind-down, price increases, sales investment, available cash, and operating projections support funding the current plan for at least 12 months from issuance of the financial statements. It cautioned that further discretionary cost cuts may be needed if results fall short.
- The company expects to incur additional losses until sales or licensing revenue is sufficient to achieve profitability. Management noted that results fluctuate and period-to-period comparisons may not indicate future performance; no specific revenue or earnings guidance was provided.
- Customer concentration is significant: three customers represented 49% of Q1 revenue. Three customers accounted for 57% of accounts receivable at March 31, with customer B alone representing 33%.
- Nephros depends on Medica under an exclusive license and supply agreement expiring December 31, 2025. It had approximately $2.2 million of remaining 2023 minimum-purchase commitments as of March 31, against a $4.1 million annual minimum.
- Other disclosed risks include the ability to sustain growth and fund operations, product liability or recalls, regulatory compliance and approvals, competition and pricing, supplier and distributor issues, and intellectual-property protection. The company reported no off-balance-sheet arrangements and no material change in internal control over financial reporting; management concluded disclosure controls were effective.
Important facts for investors to verify
- Whether revenue growth persists after excluding the approximately $0.6 million emergency-response order, and whether margins remain within management’s target range.
- Whether cash generation and the stated 12-month liquidity outlook hold up against operating losses, working-capital needs, and Medica purchase commitments.
- Collection timing and credit exposure for major customers, particularly customer B’s share of receivables.
- The status and value of assets expected from SRP, including HDF2 intellectual property, and the effect of the wind-down on future expenses and opportunities.
- Whether supplier, regulatory, product-liability, and other risks described in the filing materially affect sales, costs, or access to capital.